Claritin/Singulair combo stumbles
Executive Summary
Phase III trials of a combination of the antihistamine Claritin and the asthma agent Singulair "did not demonstrate a statistically significant improvement in the treatment of seasonal allergic rhinitis compared to each product administered separately," Schering-Plough and Merck say. The firms will continue to evaluate the results and may conduct additional studies. The combo is under development via a joint venture formed in 2000 (1"The Pink Sheet" May 29, 2000, p. 22). Merck is conducting Phase III trials of Singulair monotherapy for allergic rhinitis...